<p>根据最近向证券交易委员会的披露，Price T Rowe Associates Inc. MD 在第四季度收购了 Grail, Inc.（NASDAQ:GRAL - 免费报告）的新股份。该公司收购了 24,520 股，价值约 438,000 美元。截至最近的 SEC 备案，Price T Rowe Associates Inc. MD 持有 Grail 约 0.07% 的股份。</p>
<ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
<p>其他一些对冲基金最近也对该公司的持仓进行了调整。C2P Capital Advisory Group LLC 以 Prosperity Capital Advisors 的名义在第四季度购买了 Grail 的新股份，价值约 244,000 美元。Moloney Securities Asset Management LLC 在第四季度收购了价值约 559,000 美元的 Grail 新股份。Rhumbline Advisers 在第四季度收购了价值约 456,000 美元的 Grail 新股份。Wesbanco Bank Inc.在第四季度购买了价值 523,000 美元的 Grail 新股份。最后，Slow Capital Inc.在第四季度购买了价值 2,379,000 美元的 Grail 新股份。</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司对 GRAL 进行了评估。Canaccord Genuity Group 在 4 月 21 日的研究报告中开始覆盖 Grail。他们对该股票给予了 “买入” 评级，并设定了 32.00 美元的目标价。摩根士丹利在 3 月 18 日的研究报告中将 Grail 的目标价从 16.00 美元上调至 20.00 美元，并给予该股票 “持平” 评级。</p>
<ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
<p><strong>查看我们对 GRAL 的最新分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他 Grail 新闻中，总裁 Joshua J. Ofman 在 5 月 2 日的交易中出售了 48,213 股股票。该股票以平均价格 33.93 美元出售，总价值为 1,635,867.09 美元。交易后，总裁现在持有 511,460 股公司股票，价值约 17,353,837.80 美元。这代表着他们持股比例下降了 8.61%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席财务官 Aaron Freidin 在 3 月 7 日的交易中出售了 1,816 股股票。这些股票以平均价格 31.20 美元出售，总价值为 56,659.20 美元。交易完成后，首席财务官现在直接持有 335,170 股公司股票，价值约 10,457,304 美元。这代表着他们的持股比例下降了 0.54%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 194,948 股公司股票，价值 6,583,130 美元。目前，1.85% 的股票由公司内部人士持有。</p>
<h2>Grail 价格表现</h2>
<p>NASDAQ GRAL 的股票在周三以 42.89 美元开盘。该股票的 50 日移动平均线为 29.69 美元，200 日移动平均线为 26.15 美元。Grail, Inc.的 1 年最低价为 12.33 美元，最高价为 63.99 美元。</p>
<p>Grail（NASDAQ:GRAL - 获取免费报告）最近在 5 月 13 日公布了季度财报。该公司报告季度每股收益（EPS）为（3.10 美元），超出分析师一致预期的（4.03 美元）0.93 美元。该季度公司收入为 3184 万美元，而分析师预期为 3580 万美元。股票研究分析师预计 Grail, Inc.在当前年度将发布-15.15 的每股收益。</p>
<h2>Grail 简介</h2>
<p>（免费报告）</p>
<p>GRAIL, Inc.是一家商业阶段的医疗保健公司，专注于开发早期癌症检测技术。它利用机器学习、软件和自动化技术在早期阶段检测和识别多种致命癌症类型。该公司由 Jeffrey T.创立。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票而非 Grail</li>
<li>投资 5G 技术的顶级股票</li>
<li>NVIDIA 股票因乐观消息飙升：能涨多高？</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>为什么波音在最新发展后可能准备起飞</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>eBay 接近重大突破：是时候购买这只低调赢家了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Grail 吗？</h2>
<p>在考虑 Grail 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Grail 并不在名单上。</p>
<p>虽然 Grail 目前在分析师中获得了持平评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GRAL

普信金融

<p>T Rowe Associates Inc. MD 在第四季度收购了 24,520 股 Grail, Inc.（纳斯达克代码：GRAL），价值约 438,000 美元。其他对冲基金也增加了对 Grail 的持股。分析师们设定了新的价格目标，Canaccord Genuity 发布了 “买入” 评级，目标价为 32.00 美元，而摩根士丹利将目标价从 16.00 美元上调至 20.00 美元。Grail 报告的季度每股收益为（3.10 美元），超出预期，收入为 3184 万美元。该股票开盘价为 42.89 美元，1 年区间为 12.33 美元至 63.99 美元</p>

<p>Price T Rowe Associates Inc. MD acquired a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm acquired 24,520 shares of the company's stock, valued at approximately $438,000. Price T Rowe Associates Inc. MD owned approximately 0.07% of Grail as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会的披露，Price T Rowe Associates Inc. MD 在第四季度收购了 Grail, Inc.（NASDAQ:GRAL - 免费报告）的新股份。该公司收购了 24,520 股，价值约 438,000 美元。截至最近的 SEC 备案，Price T Rowe Associates Inc. MD 持有 Grail 约 0.07% 的股份。</p>
</div><ul>
<li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li>
</ul>
<div class="lb-trans"><ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
</div><p>A number of other hedge funds have also recently made changes to their positions in the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Grail during the fourth quarter worth about $244,000. Moloney Securities Asset Management LLC acquired a new stake in Grail in the fourth quarter valued at approximately $559,000. Rhumbline Advisers acquired a new stake in Grail in the fourth quarter valued at approximately $456,000. Wesbanco Bank Inc. bought a new stake in Grail during the fourth quarter worth $523,000. Finally, Slow Capital Inc. bought a new stake in Grail during the fourth quarter worth $2,379,000.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也对该公司的持仓进行了调整。C2P Capital Advisory Group LLC 以 Prosperity Capital Advisors 的名义在第四季度购买了 Grail 的新股份，价值约 244,000 美元。Moloney Securities Asset Management LLC 在第四季度收购了价值约 559,000 美元的 Grail 新股份。Rhumbline Advisers 在第四季度收购了价值约 456,000 美元的 Grail 新股份。Wesbanco Bank Inc.在第四季度购买了价值 523,000 美元的 Grail 新股份。最后，Slow Capital Inc.在第四季度购买了价值 2,379,000 美元的 Grail 新股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms have weighed in on GRAL. Canaccord Genuity Group assumed coverage on Grail in a research report on Monday, April 21st. They issued a &#34;buy&#34; rating and a $32.00 price objective on the stock. Morgan Stanley upped their target price on Grail from $16.00 to $20.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, March 18th.</p>
<div class="lb-trans"><p>几家研究公司对 GRAL 进行了评估。Canaccord Genuity Group 在 4 月 21 日的研究报告中开始覆盖 Grail。他们对该股票给予了 “买入” 评级，并设定了 32.00 美元的目标价。摩根士丹利在 3 月 18 日的研究报告中将 Grail 的目标价从 16.00 美元上调至 20.00 美元，并给予该股票 “持平” 评级。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on GRAL</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GRAL 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Grail news, President Joshua J. Ofman sold 48,213 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $1,635,867.09. Following the transaction, the president now owns 511,460 shares of the company's stock, valued at approximately $17,353,837.80. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the transaction, the chief financial officer now directly owns 335,170 shares in the company, valued at approximately $10,457,304. This represents a 0.54% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,948 shares of company stock valued at $6,583,130. 1.85% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Grail 新闻中，总裁 Joshua J. Ofman 在 5 月 2 日的交易中出售了 48,213 股股票。该股票以平均价格 33.93 美元出售，总价值为 1,635,867.09 美元。交易后，总裁现在持有 511,460 股公司股票，价值约 17,353,837.80 美元。这代表着他们持股比例下降了 8.61%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席财务官 Aaron Freidin 在 3 月 7 日的交易中出售了 1,816 股股票。这些股票以平均价格 31.20 美元出售，总价值为 56,659.20 美元。交易完成后，首席财务官现在直接持有 335,170 股公司股票，价值约 10,457,304 美元。这代表着他们的持股比例下降了 0.54%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 194,948 股公司股票，价值 6,583,130 美元。目前，1.85% 的股票由公司内部人士持有。</p>
</div><h2>Grail Price Performance</h2>
<div class="lb-trans"><h2>Grail 价格表现</h2>
</div><p>Shares of NASDAQ GRAL opened at $42.89 on Wednesday. The stock's 50-day moving average is $29.69 and its 200 day moving average is $26.15. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99.</p>
<div class="lb-trans"><p>NASDAQ GRAL 的股票在周三以 42.89 美元开盘。该股票的 50 日移动平均线为 29.69 美元，200 日移动平均线为 26.15 美元。Grail, Inc.的 1 年最低价为 12.33 美元，最高价为 63.99 美元。</p>
</div><p>Grail (NASDAQ:GRAL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($3.10) EPS for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. The company had revenue of $31.84 million during the quarter, compared to analysts' expectations of $35.80 million. Equities research analysts expect that Grail, Inc. will post -15.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Grail（NASDAQ:GRAL - 获取免费报告）最近在 5 月 13 日公布了季度财报。该公司报告季度每股收益（EPS）为（3.10 美元），超出分析师一致预期的（4.03 美元）0.93 美元。该季度公司收入为 3184 万美元，而分析师预期为 3580 万美元。股票研究分析师预计 Grail, Inc.在当前年度将发布-15.15 的每股收益。</p>
</div><h2>Grail Profile</h2>
<div class="lb-trans"><h2>Grail 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.</p>
<div class="lb-trans"><p>GRAIL, Inc.是一家商业阶段的医疗保健公司，专注于开发早期癌症检测技术。它利用机器学习、软件和自动化技术在早期阶段检测和识别多种致命癌症类型。该公司由 Jeffrey T.创立。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Grail</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>NVIDIA Stock Surges on Bullish News: How High Could It Climb?</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Why Boeing May Be Ready to Take Off After Latest Developments</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Grail</li>
<li>投资 5G 技术的顶级股票</li>
<li>NVIDIA 股票因乐观消息飙升：能涨多高？</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>为什么波音在最新发展后可能准备起飞</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>eBay 接近重大突破：是时候购买这只低调赢家了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GRAL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Grail Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Grail 吗？</h2>
</div><p>Before you consider Grail, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Grail 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Grail 并不在名单上。</p>
</div><p>While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Grail 目前在分析师中获得了持平评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

普信金融公司（T Rowe Associates Inc. MD）收购 Grail, Inc.（纳斯达克代码：GRAL）的新股